行情

CANF

CANF

灿菲特生物制药
AMEX

实时行情|Nasdaq Last Sale

1.900
+0.010
+0.53%
盘后: 1.850 -0.05 -2.63% 18:54 01/15 EST
开盘
1.850
昨收
1.890
最高
1.930
最低
1.820
成交量
40.49万
成交额
--
52周最高
2.950
52周最低
1.080
市值
2,937.21万
市盈率(TTM)
-1.1685
分时
5日
1月
3月
1年
5年
新闻
财报
公告
公司事件
分析
简况
CANF：多个“射门得分”使有成千上万的机会…
NYSE:CANF
Benzinga · 01/01 06:41
Can-Fite Receives Israel Ministry Of Health Approval To Conduct Research With Cannabinoids In Cancer, Inflammation And Obesity At Company Discovery Labs
- State-of-the-art in house labs leveraged for cost and time efficient development of high-value cannabinoid assets - Cannabinoids bind to A3 adenosine receptor (A3AR), which is over-expressed in pathological
 State-of-the-art in house labs leveraged for cost and time efficient development of high-value cannabinoid assets - Cannabinoids bind to A3 adenosine receptor (A3AR), which is over-expressed in pathological · 2020/12/15 12:07
大麻周：更多法案通过，联合国投票，乔·罗根，Will.i.am，阿芙莉亚，树冠和收入
It was a historic week for cannabis.
Benzinga · 2020/12/05 21:52
The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 12)
Benzinga · 2020/11/13 12:40
Can-Fite to Present its NASH Program in Fireside Chat at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020
finviz · 2020/11/09 11:00
The Daily Biotech Pulse: Vertex Pulls Plug On Protein Deficiency Drug, FDA Nod For Regeneron's Ebola Treatment, Can Fite Issues Psoriasis Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 14)
Benzinga · 2020/10/15 12:03
Can-Fite to Host Conference Call to Update Shareholders on Positive Interim Results of its Phase III Psoriasis Study on October 15, 2020
finviz · 2020/10/13 11:00
Can-Fite to Host Conference Call to Update Shareholders on Positive Interim Results of its Phase III Psoriasis Study on October 15, 2020
finviz · 2020/10/13 11:00
更多
财务预测
每股收益每股净资产每股现金流
实际值（美元）
预测值（美元）
利润表更多
净利润营业总收入营业利润
净利润（美元）
同比（%）
资产负债表更多
总资产（美元）
总负债（美元）
资产负债率（%）
现金流表更多
经营现金流投资现金流筹资现金流
经营现金流（美元）
同比（%）
了解CANF最新的财务预测，通过CANF每股收益，每股净资产，每股现金流等数据分析灿菲特生物制药近期的经营情况，然后做出明智的投资选择。
分析师评级

2位分析师的综合评级

买入

免责声明：分析师观点仅供投资者决策参考，不构成任何买卖投资建议。

目标价格预测
分析师预测CANF价格均价为5.00，最高价位5.00，最低价为5.00。
EPS
机构持股
总机构数: 9
机构持股: 35.60万
持股比例: 2.30%
总股本: 1,545.90万
类型机构数股数
增持
1
3.37万
建仓
3
22.49万
减持
4
5
平仓
1
913
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-0.34%
制药与医学研究
+0.21%
高管信息
Chairman/Director
Ilan Cohen
Chief Executive Officer/Director
Pnina Fishman
Chief Financial Officer/Chief Operating Officer
Motti Farbstein
Director
Guy Regev
Director
Abraham Sartani
Director
Israel Shamay
  • 分红
  • 拆股
  • 内部人交易
暂无数据
  • 全部
  • 财务报告
  • 内部人交易
更多
注册即可获得3个月
免费美股Level2深度行情
(Nasdaq Totalview)
立即领取
CANF 简况
Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases. The Company has a research infrastructure including research laboratories and animal house facilities run by the development team. Can Fite Biofarma Ltd signed distribution contracts with a Kwang Dong Pharmaceutical Co. allowing distribution of CF101 for arthritis in Korea and Seikagaku Corp. for distribution in Japan. The Company operates three subsidiaries, Ultratrend Ltd, EyeFite Ltd and OphathaliX Inc.
展开
热门股票
代码
价格
涨跌幅

微牛提供Can Fite Biopharma Ltd(AMEX-CANF)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的CANF股票新闻，以帮助您做出投资决策。

模拟交易：模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CANF股票基本功能。